# Expert Assessment: GluN2B-Mediated Thalamocortical Glymphatic Tau Clearance
## Druggability: Moderate-to-Low
The hypothesis proposes GRIN2B modulation as a gateway to enhanced tau clearance via glymphatic flow. While GRIN2B is a validated target with known pharmacological agents, **translational viability faces substantial barriers**.
**Direct GluN2B modulators exist:**
- Ifenprodil (historical, off-patent)
- Ro 25-6981 (selective antagonist, research use only)
- CERC-301/MK-8658 (Concert Therapeutics/Merck) — failed in major depression Phase II (NCT02140216)
- Nelotanserin (Axovant) — abandoned in Lewy body dementia
The fundamental problem: global GluN2B antagonism produces dose-limiting CNS toxicity (psychotomimetic effects, dissociation). **Circuit-specific targeting remains unresolved.** Even if thalamocortical synchrony could be enhanced, off-target effects on hippocampal/cortical GluN2B signaling risk excitotoxic disruption rather than neuroprotection.
## Competitive Landscape
**Indirect approaches dominate:**
| Company | Approach | Status |
|---------|----------|--------|
| Eli Lilly | Solanezumab (anti-Aβ, not tau) | Failed; shifted to donanemab |
| Biogen/Ionis | BIIB080 (anti-tau ASO) | Phase Ib/IIa (NCT05316723) |
| UCB | Prasinezumab (anti-α-syn) | Parkinson's trials |
| Novartis | GSK-3β inhibitors | Preclinical/failed |
**Glymphatic enhancement strategies** (sleep optimization, ADH manipulation, perivascular targeting) are earlier stage but avoid excitotoxicity concerns entirely.
## Key Feasibility Concerns
1. **Glymphatic reproducibility** — Human imaging data remain inconclusive; animal models don't fully translate
2. **Thalamus as "glymphatic hub"** — Mechanistic evidence is associative, not causal
3. **Tau bidirectional relationship** — Whether enhancing clearance meaningfully alters clinical trajectory is unproven
## Verdict
While mechanistically intriguing, this hypothesis overstates control at each causal step. A more pragmatic approach would target sleep architecture directly (orexin antagonists, e.g., suvorexant) to enhance slow-wave-dependent glymphatic activity, avoiding GRIN2B's narrow therapeutic window. Cost: ~$2B and 10+ years to validate the full pathway clinically.